Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP.
Myoepithelial carcinoma is one of several new entities added to the updated classification of salivary gland tumors by the WHO in 1991. This tumor most frequently occurs in parotid gland. This is the first report presenting the tumor in floor of the mouth. It is a rare and prognostic poor cancer. Especially, there was not good therapy for recurrent cases. We treated the patient with repeated recurrences three times and presented in bilateral parapharyngeal space to skullbase in this time. We targeted function preservation and complete cure. In order to accomplish the both objections he received the superselective intra-arterial chemotherapy infused high-dose CDDP with radiation. We confirmed tumor free in FDG-PET in 2 months after the treatment. Now, we cannot detect any recurrence in 7 months after the treatment and he can eat anything and communicate anybody as before treated. We should follow-up him carefully.
Takayama
Osamu
O
Department of Otolaryngology, Head and Neck Surgery, Tochigi Cancer Center, 4-9-13 Younan, Utunomiya, Tochigi 320-0834, Japan.
Yokoyama
Junkichi
J
Ito
Shin
S
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007269:Injections, Intra-Arterial; D008279:Magnetic Resonance Imaging; D008297:Male; D009060:Mouth Floor / Q000473:pathology*; D009208:Myoepithelioma / Q000473:pathology* / Q000628:therapy*; D011879:Radiotherapy Dosage; D012468:Salivary Gland Neoplasms / Q000473:pathology* / Q000628:therapy*